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Breakthrough in treatment of Alzheimer’s disease with a shift from irrational dangerous chelation therapy to rational safe evidence
based oral zinc therapy. Evidence based medicine: After synthesizing the best available clinical evidence I conclude that oral zinc
therapy is a conscientious choice for treatment of free copper toxicosis in individual patients with Alzheimer’s disease. Hypothesis
1: Age related free copper toxicosis is a causal factor in pathogenesis of Alzheimer’s disease. There are 2 neurodegenerative
diseases with abnormalities in copper metabolism: (a) the juvenile form with degeneration in the basal ganglia (Wilson’s disease)
and (b) the age related form with cortical neurodegeneration (Alzheimer’s disease). Initially the hypothesis has been that
neurodegeneration was caused by accumulation of copper in the brain but later experiences with treatment of Wilson’s disease led
to the conviction that free plasma copper is the toxic form of copper: it catalyzes amyloid formation thereby generating oxidative
stress, free radicals and degeneration of cortical neurons. Hypothesis 2: Oral zinc therapy is an eﬀective and safe treatment of free
copper toxicosis in Alzheimer’s disease. Proposed dosage: 50mg elementary zinc/day. Warning: Chelation therapy is irrational and
dangerous in treatment of copper toxicosis in Alzheimer’s disease.
1.Introduction
Title of the Study. The title: “Paradigm shift in treatment of
Alzheimer’s disease: zinc therapy a conscientious choice for
care in individual patients” is comparable with the title of
the article titled: “Paradigm shift in treatment of Wilson’s
disease: zinc therapy now treatment of choice” that I pub-
lished in Brain and Development in 2006 [1]. The title pre-
ludes on the idea that lessons learnt from earlier clinical
studies on zinc therapy in patients with free copper toxicosis
in Wilson’s disease have been very helpful in making the
conscientious choice for zinc therapy for individual patients
with Alzheimer’s disease now.
Aim of the Current Review. The purpose of this analytic re-
view is threefold: (1) to cumulate evidence for the hypothesis
thatAlzheimer’sdiseasecausedbyanage-relateddisturbance
of copper metabolism (type 2 free copper toxicosis) that
leads to oxidative stress and neurodegeneration. (2) to
provide evidence for the hypothesis that causal treatment
of individual patients with Alzheimer’s disease can best be
done with antioxidative oral zinc therapy. (3) to warn for the
tragic misconception that chelating agents are qualiﬁed for
treatment of free copper toxicosis.
Alzheimer’s Disease and Copper Metabolism. This disorder is
a common neurological disease and aﬀects about 250,000
individuals in the Netherlands. Neuropathological research
has shown that the plaques detected in the brain of patients
with Alzheimer’s disease contain deposits of amyloid and
abnormal neuroﬁbrils, and the cortical neurons to be
withered. The prognosis of Alzheimer’s disease is poor. The
disease is slowly progressive and spontaneous recovery has
never been documented. It is essential to clarify the path-
ogenesisofthedisease,toenableearlydiagnosisofthedisease
by means of laboratory testing [2]. As long as the cause of the
disease is not exactly known, causal therapy is not possible.
Inﬂammatory, vascular, and genetic factors are probably
important to the disease pathogenesis, but metals, especially
“free-metals” like free copper and free iron may be involved2 International Journal of Alzheimer’s Disease
in catalyzing amyloidosis and catalyzing the Fenton’s reac-
tion, leading to the generation of free radicals like hydrogen
peroxide (H2O2) that can damage neurons. Speciﬁcally,
free copper is an exchangeable pool of copper in serum
which is probably in a Cu(I) oxidative state and is loosely
bound and exchanged among amino acids, small peptides,
albumin, and alpha 2 macroglobulin. This type of copper
is intrinsically toxic since it can enter Fenton-like reactions
triggering free radical generation [3]. Moreover, for its low-
molecular-weight nature it can easily cross the blood-brain
barrier as previously [4] and very recently [5] demonstrated
in diverse experimental models in vivo. In Wilson’s disease
degeneration upon free copper excess primary hits the liver,
the organ which tightly controls metal homeostasis in the
body.ThisistrueincasesofsevereimpairmentoftheATPase
7B function, which have usually a juvenile presentation [3].
Freecoppertoxicosis inAD is sensitively milder, eventhough
very mild eﬀects on AD liver have been reported [6, 7].
A study has shown that the levels of the metal-binding
protein metallothionein may be reduced in Alzheimer’s
disease [8], and another neurodegenerative disease, hepato-
lenticular degeneration or Wilson’s disease is known to be
caused by free copper poisoning [9, 10].
While a debate did exist for many years concerning a
positive or negative eﬀect of plasma copper on AD, free
copper results from clinical studies carried out on Alz-
heimer’s disease patients so far are univocal, demonstrating
ad e t r i m e n t a le ﬀect of this type of copper on Alzheimer’s
disease worsening. The works from Squitti and colleagues
have shown elevated levels of free copper speciﬁcally in
Alzheimer’s disease, that the free copper disarrangement
correlated with worsen clinical status of Alzheimer’s disease
patients, with a worsen prognosis, and very recently with a
status of mild cognitive impairment [11–16]. These studies
have been conﬁrmed by other groups from diverse countries
[17, 18].
Danzeisen and colleagues [19] reported that free copper
is not a suitable marker for copper, apparently questioning
results from other authors [6, 13], although no authors ever
took into account this possibility. Free copper is, instead,
one of the seven diagnostic tests which may help to ensure
that the correct diagnosis of Wilson’s disease is made [3, 9].
On the other hand, copper concentration in the liver is the
most robust marker of copper status in the body, but the
measurement is invasive. Ceruloplasmin can be a quite good
marker of body copper status, especially in condition of a
copper deﬁciency, as for example on a copper-deﬁcient reg-
imen, which results in ceruloplasmin serum decreases [20].
2. Neurodegeneration and Copper Metabolism
There are many neurodegenerative disorders, such as Alz-
heimer’s disease, lenticular degeneration in Wilson’s disease,
Parkinson’s disease, Huntington’s disease, amyotrophic lat-
eral sclerosis, age-related macular degeneration, and hered-
itary ataxia. The pathogenesis of most of these diseases is
unknown. Wilson’s disease is the only exception: neurode-
generation of the basal ganglia of the brain is caused by free
copper toxicosis [3, 10]. Wilson’s disease became the ﬁrst
neurodegenerative disease for which causal treatment was
discovered. Causal therapy is possible: zinc therapy is a safe
and eﬀective treatment of free copper toxicosis [21].
3. Amyloidosis and Free Copper
The characteristic Alzheimer plaques contain accumulations
of amyloid. These deposits also have excess copper and iron.
Research into development of drugs for Alzheimer’s disease
target at amyloid accumulation in the brain. Amyloid is also
found in the macula of patients with age-related macular
degeneration. Zinc supplementation aiming at decrease of
oxidative stress has been found to be eﬀective [22].
Amyloidosis in Type 2 Diabetes Mellitus. amyloid deposits ac-
cumulate in plaques in pancreatic cells, a process that is
catalyzed by free copper. Hydrogen peroxide is generated
during the aggregation of amylin peptide into amyloid. The
formation of hydrogen peroxide is greatly stimulated by free
copper and could cause progressive degeneration of islet cells
in type 2 diabetes mellitus [23].
4. Chelation Therapy in Wilson’s Disease
Initially, Wilson’s disease was thought to be caused by toxic
eﬀects of copper deposits that had been accumulated in
the basal ganglia, and metalchelators such as BAL and pen-
icillamine were given in order to liberate copper from the
stores and increase the excretion of copper via the urine [9].
Indeed for about 50 years penicillamine has been used for
thetreatmentofcopperaccumulatedinWilson’sdisease,and
the toxic chelating agent became accepted worldwide as the
treatment of choice: survival was thought to be prolonged
by penicillamine and signs of copper accumulation, such as
Kayser-Fleischer rings, diminished or disappeared [9].
The Chelation Therapy Fallacy. Evidence-based medicine
disputes eﬃcacy, safety, and much of the theory behind che-
lation therapy. The fatal ﬂaw of the copper chelating strategy
is that it is based on the method of induction and that it was
developed without any deductive, evidence-based reasoning
and without any clinical trials having been performed.
5. Chelation Therapy in Alzheimer’s Disease
An article on nanochelationtherapy published in September
2005 [24] ﬁrst drew my attention to the disturbance of cop-
per homeostasis in Alzheimer’s disease. The authors referred
to two articles published by Squitti and colleagues [10, 11].
In one of these studies, Squitti et al. [25]h a dm e a s u r e d
serum copper concentrations in 47 patients with Alzheimer’s
disease, 24 patients with vascular dementia, and 44 healthy
controls.MeanfreecopperconcentrationsintheAlzheimer’s
disease patients were signiﬁcantly higher than in the vascular
dementia patient group and control group. The authors
speculated that the raised copper concentrations could play
a role in the pathogenesis of the degenerative process. In anInternational Journal of Alzheimer’s Disease 3
earlier study, the same authors had described the results of
a double-blind, placebo-controlled pilot study of the eﬀects
of chelation therapy with penicillamine (600mg/day) for 6
months in patients with Alzheimer’s disease [25]. At that
time, it was not appreciated that patients could be suﬀering
from free copper poisoning. Instead, treatment was focused
on copper accumulation, and the aim of treatment was to
increase the excretion of copper in urine, to reduce lab-
oratory measures of oxidative stress, and to slow the pro-
gression of cognitive deterioration, as measured with neu-
ropsychological tests. Thirty-four patients took part in the
study: 17 received placebo and 17 received penicillamine.
Only 9 patients in both groups completed the study. Of the
patients treated with penicillamine, 1 died of a heart infarct
and 4 experienced serious adverse events. The pilot study
was stopped prematurely by the ethics committee because
there were too many adverse events. The authors concluded
that penicillamine had not slowed the clinical progression of
the disease and that a less harmful chelating agent should be
sought. As far as I am aware, Squitti and her colleagues are
the ﬁrst investigators to have performed a controlled clinical
study on eﬃcacy and side eﬀects of chelation therapy.
6.Evidence-BasedMedicinein
Alzheimer’sDisease
Making decisions on causal drug therapy in individual pa-
tients with Alzheimer’s disease is hampered by the fact
that randomized clinical trials to base the decisions on are
not easy to ﬁnd. Nevertheless such trials are essential to
identify dangerous and worthless treatments. I found that he
clinical trial described by Squitti et al. in 2002 [25]i ss u c h
a trial. It was a real eye opener, it identiﬁed the paradoxical
eﬀect of penicillamine in Alzheimer’s disease: the trial had
to be stopped by the ethical board because of the severe
side eﬀects of the chelating agent. This paradoxical eﬀect
of penicillamine in Alzheimer’s disease reminded me of the
dangerousparadoxicaleﬀectseeninpatientswithfreecopper
toxicosis in Wilson’s disease and it stimulated me to develop
the hypothesis that free copper toxicosis might play a causal
role in Alzheimer’s disease.
In my opinion, chelating agents, including PBT1 (clio-
quinol)andPBT2[26,27],shouldbetestednomoreontheir
eﬀect on safety in treatment of patients with Alzheimer’s
disease. An ethical committee involved in the preparation
of such a clinical trial should not give permission for it
being performed. Since we know that copper metabolism
is disturbed in Alzheimer’s disease and since we know that
a randomized clinical trial with the chelating agent pen-
icillamine had to be stopped by the ethical committee
because of severe side eﬀects [25], it is irresponsible to ask
patients to give permission to participate in a clinical trial
with the chelating agent clioquinol.
7. Zinc Therapy
A randomized clinical trial testing a clear hypothesis is
needed before conclusions can be drawn about the value of
zinc supplements in the treatment of Alzheimer’s disease.
Such a clinical trial could be set up on lines similar to
the randomized clinical trial of penicillamine performed in
2002 [25]. The eﬀect of a low dose of zinc (50mg/day)
on the free copper concentration in serum, the urinary
excretion of copper, laboratory markers of oxidative stress,
and cognitive functions could be investigated in a blind,
placebo-controlled trial. In conclusion, the work of Squitti
et al. has provided data to justify the hypothesis that free
copperconcentrationsareraisedinpatientswithAlzheimer’s
disease. In my opinion, it is justiﬁed, and even desirable, to
test in a controlled study the hypothesis that the free copper
poisoning of patients with Alzheimer’s disease is amenable
to zinc therapy. A previous study suggested potential beneﬁt
of a zinc therapy in AD [28]. Moreover, a very preliminary
studywithZinctherapygavepositiveresultsincounteracting
AD progression [28]. Speciﬁcally, a previous study suggested
potential beneﬁt of a zinc therapy in AD [28]. Ten patients
were treated, all of them receiving 50mg of oral zinc bis-
(dlhydrogen aspartate) three times daily obtaining improve-
mentofmemory,understanding,communication,andsocial
contact in eight patients, as stated by the author [28]. The
discontinuationofthetreatmentdecreasedandevenreversed
the improvement, in all patients. However, these conclu-
sions have to be taken very cautiously. Even though these
limitations, a phase II, multicentre, prospective, random-
ized, double-blind, placebo-controlled, parallel group study
conducted with patients presenting a diagnosis of mild to
moderate clinical trial with the following characteristics: (a)
atreatmentdurationofatleastonefullyear,asexpectedwith
curative compound use versus symptomatic approaches; (b)
a patient-inclusion criterion based on individual serum Cu-
dysfunction evidence; (c) monitoring of Cu bioavailability
throughout the study with detection of Cu metabolism
markerssuchasfreeCu,ceruloplasmin,orCu/Znsuperoxide
dismutase levels, to prevent adverse events; (d) statistical
power (at least 75 patients per arm, placebo and treated); a
dose of zinc sulphate 400–1200mg/day, can be proposed.
8. Additional Paragraph on Very Recent Studies
on Alzheimer Research
Two very recent articles [29, 30] cast biometals in the sce-
nario of the variegated milieu of biomarkers of cerebrospinal
ﬂuid (CSF), imaging biomarkers and peripheral biomarkers
of Alzheimer’s disease under investigation. In recent years,
concentrations of CSF amyloid-β42, total Tau, and phospho-
rylated Tau, in vivo molecular imaging of intracerebral beta-
amyloid load (by the Pittsburgh Compound-B: PiB-PET),
structural and functional neuroimaging changes, or periph-
eral biomarkers (including inﬂammatory markers inter-
leukins, cytokines, oxidative stress compounds isoprostanes,
plasmaAPPmarkers(BACE1)andothermarkersofsynaptic
damage/neurodegeneration) [31–33] have been repetitively
reported as diﬀerentiating factors of Alzheimer’s disease
which also reﬂect core pathological changes of the disease,
eventually leading to full dementia. The two papers, which
disclose the potentiality of metallochemistry in clinical4 International Journal of Alzheimer’s Disease
studies on Alzheimer’s disease patients [29, 30]h a v eb e e n
preceded by numerous and heterogeneous reports exploring
the reliability of some metals, particularly copper, in char-
acterizing Alzheimer’s disease patients and cognitive wors-
ening. Besides the so many case-control studies evaluated
in a recent meta-analyses by Bucossi and coworkers [29], at
least two prospective studies did demonstrate the relevant
inﬂuence of copper dysfunction of cognitive status. Specif-
ically, (i) a community-based prospective study exploring
cognitive functions in a cohort of 3,718 elderly individuals
[34], revealed that a diet high in copper combined with a
high dietary intake of saturated fats associated with a faster
rate of cognitive decline, speciﬁcally with a lost cognition at a
rate three-times higher than expected [34]; (ii) a study on 81
subjects with mild to moderate Alzheimer’s disease patients,
clinically followed up for 1 year[15] ﬁnding that higher levels
ofcopperatthebaselinecorrelatedwithaworsenedcognitive
status at 1 year. These results are in line with the Rancho
and Bernardo study [35] which evaluated 602 men and 849
women for metals (Cu, Fe, and Zn) in association with cog-
nitive performance and revealed that women had worsened
performance in total and long-term word (but not short)
retention and higher plasma copper levels, as evaluated by
the Buschke-Fuld Selective Reminding Test, as well as poorer
concentration abilities, as tested by the Blessed Information-
Memory-Concentration Test. In their study, Bucossi and
coworkers [29] analyzed in a meta-analysis design, data
from all the serum, plasma, and CSF case-control studies
published since 1983 on Alzheimer’s disease patients, to gain
an objective evaluation of whether systemic copper variation
were associated with Alzheimer’s disease. Data from 21 stud-
ies on serum copper and 5 studies on plasma copper were
merged for a pooled total of 966 Alzheimer’s disease patients
and 831 controls which were enough to draw the conclusion
that Alzheimer’s disease patients had higher levels of serum
copper than healthy controls, suﬃcient to unambiguously
distinguish Alzheimer’s disease patients from healthy con-
trols. From a totally diﬀerent perspective the same authors
challenged the copper hypothesis in Alzheimer’s disease,
screening chromosomes from Alzheimer’s disease patients
for Wilson’s disease mutations or polymorphisms [30]. They
foundthattheWilson’sdiseaseATP7Bgene—whichisatight
control balance regulator for free copper levels in the body—
presents susceptibility loci for late-onset Alzheimer’s disease
[30]. As stated by the authors, they explored Alzheimer’s
disease chromosomes with a hypothesis-driven candidate
gene association study, to verify whether the Wilson’s disease
ATP7B gene had susceptibility loci for late-onset Alzheimer’s
disease, assuming that the free copper disproportion is true
and speciﬁcally associated with AD. Moreover, the authors
gained further results on an additional exon 12 single
nucleotide polymorphism (SNP) of the ATP7B gene associ-
ated with Alzheimer’s disease and in linkage disequilibrium
with the exon 10 SNP one, suggesting that exon 12 or
something very close to it can be a susceptibility locus for
Alzheimer’s disease (R. Squitti personal communication). It
would be surprising that genome-wide association studies
(GWASs) carried out so far have never found an association
between Alzheimer’s disease and the 13q14.3 DNA region
where the ATP7B gene lies. However, to this regard, another
paradigm shift recently proposed should to be considered
[36]. In fact, current experience with GWASs suggests that
rarer variants that are, actually, hard to detect by GWASs,
may account for the missing hereditability of Alzheimer’s
disease, estimated around 58–79%, and which plays a role
in the development and progression of Alzheimer’s disease
[37]. The paradigm recently proposed of a shift from
the “common disease—common variant hypothesis “to a
“common disease—multiple rare variants hypothesis” may
suitably ﬁt to the ATP7B gene association with Alzheimer’s
disease, since the gene is highly polymorphic but at the
same time harbors rare mutations, that in homozygous
or heterozygous compounds trait are causative of Wilson’s
disease(SquittiR.personalcommunication).Inotherwords,
it seems not premature to sustain the hypothesis that type
2 free copper toxicosis may play a causal role in age related
Alzheimer’s dementia.
Glossary
Paradigm Shift. a radical change in thinking from an ac-
cepted point of view to a new one. For instance, as to neu-
rodegeneration: from no causal treatment available to zinc
therapy for treatment of free copper toxicosis.
Deductive Method. This evidence based method aims at
identifyingerrorsandfallacies.Randomizedclinicaltrialsare
based on the deductive method.
Evidence Based Medicine. The conscientious use of current
best deductive evidence in making decisions about the care
of individual patients.
Free Copper. The small portion of plasma copper that is not
boundtoceruloplasmin.Freeplasmacopperisthetoxicform
of the metal. Copper accumulated in deposits in Alzheimer
plaques is not toxic.
Inductive Method. This method aims at veriﬁcation of the
theory but not at detecting its errors. It may lead to en-
trapment in fallacies.
Penicillamine Fallacy. The tragic, inductive method based
misconception that treatment of copper toxicosis can best be
started with a chelating agent like penicillamine.
Seductive Method. The unscientiﬁc method of choosing a
therapy simply on the basis of expert opinion, pharmaceu-
tical representatives or advertisements.
Type 1 (Juvenile) Free Copper Toxicosis in Wilson’s Disease.
Thetypeoffreecoppertoxicosiscausingoxidativestresswith
free radicals leading to neurodegeneration especially in the
basal ganglia.International Journal of Alzheimer’s Disease 5
Type 2 (Age Related, Senile) Free Copper Toxicosis in
Alzheimer’s Disease. Conscientious analytic cumulating of
the available evidence has led to the hypothesis that free
copper toxicosis does catalyze formation of amyloid in
plaques and oxidative stress causing neurodegeneration in
Alzheimer’s disease.
Zinc Therapy. A randomized clinical trial testing a clear hy-
pothesis is needed before conclusions can be drawn about
thevalueofzincsupplementsinthetreatmentofAlzheimer’s
disease. Such a clinical trial could be set up on lines similar
to the randomized clinical trial of penicillamine performed
in 2002 [25]. The eﬀect of a low dose of zinc (50mg/day)
on the free copper concentration in serum, the urinary
excretion of copper, laboratory markers of oxidative stress,
and cognitive functions could be investigated in a blind,
placebo-controlled trial. In conclusion, the work of Squitti
et al. has provided data to justify the hypothesis that free
copperconcentrationsareraisedinpatientswithAlzheimer’s
disease. In my opinion, it is justiﬁed, and even desirable,
to test in a controlled study the hypothesis that the free
copperpoisoningofpatientswithAlzheimer’sdiseaseisame-
nable to zinc therapy. A previous study suggested potential
beneﬁt of a zinc therapy in AD [28]. Moreover, a very
preliminary study with Zinc therapy gave positive results in
counteracting AD progression [28]. Speciﬁcally, a previous
study suggested potential beneﬁt of a zinc therapy in
AD [28]. Ten patients were treated, all of them receiving
50mg of oral Zinc bis-(DLhydrogenaspartate) three times
daily obtaining improvement of memory, understanding,
communication,andsocialcontactineightpatients,asstated
by the author [28]. The discontinuation of the treatment
decreasedandevenreversedtheimprovement,inallpatients.
However, these conclusions have to be taken very cautiously.
Even though these limitations, a phase II, multicentre,
prospective, randomized, double-blind, placebo-controlled,
parallel group study conducted with patients presenting a
diagnosisofmildtomoderateclinicaltrialwiththefollowing
characteristics: (a) a treatment duration of at least one
full year, as expected with curative compound use versus
symptomatic approaches; (b) a patient-inclusion criterion
based on individual serum Cu-dysfunction evidence; (c)
monitoring of Cu bioavailability throughout the study
with detection of Cu metabolism markers such as free
Cu, ceruloplasmin, or Cu/Zn superoxide dismutase levels,
to prevent adverse events; (d) statistical power (at least
75 patients per arm, placebo and treated); a dose of Zinc
Sulphate 400–1200mg/day, can be proposed.
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